Program
treprostinil hexadecyl ester
Also written as “Treprostinil Palmitil Inhalation Powder”, “Treprostinil Palmitil” and “TPIP F2”.
Its studies are mostly in Hypertension, Pulmonary · Pulmonary Arterial Hypertension · Lung Diseases, Interstitial, led by Insmed.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Insmed | 126 open or running | phase 3since Dec 6, 2022 | Mar 8, 2021 | Dec 31, 2026phase 3 · NCT05649748 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 8, 2021First study: phase 2 study in Pulmonary Arterial HypertensionFirst studyNCT04791514 · 1 enrolled · United States
- Nov 24, 2021Phase 2 study in Pulmonary Arterial HypertensionNCT05147805 · 102 enrolled · United States, Argentina, Australia and more
- Dec 10, 2021Phase 2 study in Hypertension, PulmonaryNCT05176951 · 39 enrolled · Argentina, Australia, Belgium and more
- Dec 6, 20222 phase 3 studiesNCT05649748, NCT05649722
- Oct 16, 2023Phase 1 study in Healthy VolunteersNCT06091579 · 42 enrolled · United States
- Jul 28, 2025Phase 1 study in Healthy VolunteersNCT07102316 · 42 enrolled · United States
- Sep 10, 2025Phase 3 study in Hypertension, PulmonaryNCT07179380 · 344 planned · United States, Argentina, Australia and more
- Nov 14, 2025Phase 3 study in Hypertension, PulmonaryNCT07234032 · 344 planned · United States, Czechia, France and more
- Mar 13, 2026Phase 3 study in Pulmonary Arterial HypertensionNCT07481981 · 344 planned · United States, Argentina, Australia and more
- Jun 8, 2026Phase 1 study in Hepatic ImpairmentNCT07643155 · 30 planned · United States
- Sep 1, 2026Phase 3 study in Lung Diseases, InterstitialNCT07805785 · 800 planned · United States
Ahead
- Dec 31, 2026Primary completion: phase 3 study in Pulmonary Arterial HypertensionNCT05649748
- Feb 7, 2027Primary completion: phase 1 study in Hepatic ImpairmentNCT07643155
- Dec 28, 2028Primary completion: phase 3 study in Pulmonary Arterial HypertensionNCT07481981
- Dec 30, 2028Primary completion: phase 3 study in Hypertension, PulmonaryNCT07179380
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 12 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07805785Lung Diseases, Interstitial · United States | 3 | Recruiting | Aug 31, 2030 | 800 |
| NCT07643155Hepatic Impairment · United States | 1 | Recruiting | Feb 7, 2027 | 30 |
| NCT07481981Pulmonary Arterial Hypertension · United States, Argentina, Australia and more | 3 | Recruiting | Dec 28, 2028 | 344 |
| NCT07234032Hypertension, Pulmonary · United States, Czechia, France and more | 3 | Recruiting | Jan 22, 2031 | 344 |
| NCT07179380Hypertension, Pulmonary · United States, Argentina, Australia and more | 3 | Recruiting | Dec 30, 2028 | 344 |
| NCT07102316Healthy Volunteers · United States | 1 | Completed | Oct 25, 2025 | 42 |
| NCT06091579Healthy Volunteers · United States | 1 | Completed | Jan 12, 2021 | 42 |
| NCT05649748Pulmonary Arterial Hypertension · United States, Argentina, Austria and more | 3 | Active, not recruiting | Dec 31, 2026 | 91 |
| NCT05649722Hypertension, Pulmonary · Argentina, Australia, Belgium and more | 3 | Completed | Apr 1, 2026 | 31 |
| NCT05176951Hypertension, Pulmonary · Argentina, Australia, Belgium and more | 2 | Completed | Mar 14, 2024 | 39 |
| NCT05147805Pulmonary Arterial Hypertension · United States, Argentina, Australia and more | 2 | Completed | Mar 27, 2025 | 102 |
| NCT04791514Pulmonary Arterial Hypertension · United States | 2 | Terminated | Aug 26, 2022 | 1 |
How it is read
Names in the registry
- “Treprostinil Palmitil Inhalation Powder”, 7 entries
- “Treprostinil Palmitil”, 4 entries
- “TPIP F2”, 1 entry
- “TPIP F3”, 1 entry
Conditions, from the studies’ own filings
- Hypertension, Pulmonary, 4 studies
- Pulmonary Arterial Hypertension, 4 studies
- Lung Diseases, Interstitial, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.